Drug Profile
Research programme: drug discovery - Affibody/Amylin
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Affibody; Amylin Pharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Undefined in Sweden
- 08 Aug 2012 Amylin Pharmaceuticals has been acquired by Bristol-Myers Squibb
- 05 Oct 2010 Early research in Undefined indication in Sweden (unspecified route)